

Objectives and Expected Outcomes of the Conference

Charmaine Gauci, Superintendent of Public Health, Ministry of Health, Malta

Jürgen Rockstroh, University of Bonn

Brian West, Board of Directors, European AIDS Treatment Group

Co-chairs of the HepHIV 2017 Conference

Conference Organising Committee



- Andrew Amato-Gauci, ECDC, Sweden
- Ann Sullivan, SSAT and OptTEST, United Kingdom
- Ann-Isabelle von Lingen, EATG, Belgium
- Brian West, EATG, Belgium (co-chair)
- Charmaine Gauci, Ministry of Health, Malta (local chair)
- Eberhard Schatz, Correlation Hepatitis C Initiative, the Netherlands
- Fiona Godfrey, EASL, Switzerland
- George Galea, Ministry of Health, Malta
- Jeff Lazarus, CHIP, Rigshospitalet, University of Copenhagen, Denmark
- Jens Lundgren CHIP, Rigshospitalet, University of Copenhagen, Denmark
- John de Wit, Utrecht University, the Netherlands
- Jürgen Rockstroh, HIV Outpatient Clinic at the University of Bonn, Germany (co-chair)
- Ludmila Maistat, ICF, Alliance for Public Health, Ukraine
- Martin Donoghoe, WHO Regional Office for Europe, Denmark
- Per Slaaen Kaye, Euro HIV EDAT, Denmark
- Pierre Van Damme, Viral Hepatitis Prevention Board, Belgium
- Stefan Mauss, Center for HIV and Hepatogastroenterology, Germany
- Tatjana Reic, ELPA, Belgium
- Tom Platteau, Institute of Tropical Medicine, Belgium
- Wim Zuilhof, STI AIDS Netherlands, the Netherlands



Endorsing Organisations

THE HEPHIV 2017 CONFERENCE HAS ENDORSEMENT FROM















Social Programme

HIV and Viral Hepatitis: Challenges of Timely Testing and Care

Welcome Reception

Tuesday, 31 January 7.30-10.00 pm Corinthia Hotel St. Julians, STJ 3301

MALTA

Tel: +356 2137 4114 - Fax: +356 2137 4039

Website: http://www.corinthia.com/hotels/malta_stgeorgesbay/



Conference Dinner

Wednesday, 1 February 8.00 pm

The Casino Maltese

247 Republic St, Valletta, Malta

Tel. +356 2133 0539

Website: http://www.thecasinomaltese.com/index.html







HepHIV 2017 Conference Objectives



- To further improve HIV and viral hepatitis testing and linkage to care by engaging stakeholders and exchange experiences and best practices, as well as presenting the latest evidence within the fields
- The HepHIV2014 conference ended with a call to action which the HepHIV2017 Conference will follow up on.



HEPHIV2014 CALL FOR ACTION

The HepHIV2014 Conference: Challenges of Timely Testing and Care was held in Barcelona, 5-7 October 2014, coorganised by leading stakeholders in the fields of HIV and viral hepatitis. This Call for Action has been developed by the HIV in Europe Steering Committee and HepHIV2014 Scientific Committee based on input at the conference.

1. Surveillance of viral hepatitis

Assess, nationally and regionally, how many people are infected with viral hepatitis (B and C, acute and chronic), their fibrosis stage, how many present late, and how many remain unidiagnosed, over time and by key population, in order to monitor trends and to target interventions better.

2. Defining late diagnosis of viral hepatitis for medical care

Support further consultation to establish a simple and lasting consensus definition for late presentation of viral hepatitis to improve surveillance and enable monitoring of health systems and testing strategies.

3. Testing modalities and targeted testing and communication

Promote multiple testing platforms in community settings, healthcare facilities and the home, with special attention to cost and cost-effectiveness and the possibility of testing all three blood-borne viruses at the same time.

Involve key communities in the tailoring of testing and health promotion messages to their audiences.

4. Indicator-condition-guided testing

Implement indicator-condition-guided HIV testing broadly in healthcare settings, especially general practices.

Develop the evidence to support the concept of indicator-condition-guided testing for viral hepatitis.

5. Health policy strategies

Correlate national health policy strategies with public health outcomes for viral hepatitis, HIV and TB, comparing the Eastern and Western European regions as well as the European Union and the rest of the European Region. Advocate for expansion and support the funding of successful harm-reduction models, such as that developed by Ukraine and adoption of international standards in national strategies.

6. Synergy of infectious disease efforts

Facilitate collaboration between HIV, HBV, HCV, STI and TB activities in research, policy, health promotion, surveillance, testing and education – at the regional, European Union and national levels and among civil society including representatives of key populations.

7. Continuum of care

Develop robust data to inform each component of the continuum of care for viral hepatitis and for HIV, including linkages to affordable state-of-the-art treatment and interventions for prevention and testing.

8. Affordability

Make HIV and viral hepatitis (HBV and HCV) treatment affordable by working to lower drug prices and ensuring that both domestic and international funders contribute to financing the treatment of both conditions.

Political leadership

Renewed political leadership of governments, the European Union and international agencies in the European Region is crucial to address the important challenges in viral hepatitis and HIV. Policies and public health interventions need to be based on existing scientific evidence and validated guidelines to inform viral hepatitis and HIV policies and programmes.

For more information, see http://hiveurope.eu/Conferences/HepHIV2014-Conference






- 268 participants from 42 countries (HepHIV 2014 in Barcelona: 250; Copenhagen, 2012: 323)
- Clinicians 17%
- Community representatives 32.8%
- Policymakers/Public Health Institutions 17.1%
- Social scientists, epidemiologists, statisticians
 16%
- Media 4.1%
- Industry 13%.

Programme



- Plenary sessions (5)
- Two round tables and one panel discussion (new)
- Parallel abstract-driven sessions (4)
- Posters
 - Important part of the programme
 - Wednesday 12:30-13:30 and 15:35-16:05, and Thursday 11:45-12:45
- Social programme
 - Reception and conference dinner
- Side meetings
 - OptTEST and EuroHIVEdat meetings
 - Testing Week Meeting, Wednesday 12:30-13:30
 - And others...



Expected Outcomes



- Overview on where we are in testing and linkage to care and what are the main priorities and challenges in the years to come
- Greater understanding of how to improve monitoring and surveillance and use this to impact policy and programmes to increase testing and treatment uptake
- How to further improve link between HIV, viral hepatitis and other infectious diseases to create better synergies with a patient-centred focus

Get social with us!



 Follow news from the conference and give your feedback by using the hashtag #HepHIV2017



 Answer questions, vote and interact during sessions. To do so vote live on live.voxvote.com or download the app

VoxVote. PIN: 32638



Thanks to our Sponsors & Collaborators



The HepHIV 2017 Conference: HIV and Viral Hepatitis: Challenges of Timely Testing and Care is held in conjunction with the Maltese presidency of the Council of the EU

The HepHIV 2017 conference is funded by the HIV in Europe Initiative



that has received unrestricted funding from:

Platinum partner



Gold partners





Silver partner



Additional conference support from:





The HepHIV 2017 Conference has endorsement from:

















The OptTEST Symposium has received funding from the OptTEST Project:







HEPHIV2017 CONFERENCE **PROGRAMME** AND ABSTRACT BOOK HepHIV2017 CONFERENCE **HIV AND VIRAL HEPATITIS:** CHALLENGES OF TIMELY TESTING AND CARE